Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis C

  Free Subscription


Articles published in Gastroenterology

Retrieve available abstracts of 73 articles:
HTML format
Text format



Single Articles


    October 2017
  1. JOHN M, Metwally M, Mangia A, Romero-Gomez M, et al
    TLL1 rs17047200 Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C.
    Gastroenterology. 2017 Oct 6. pii: S0016-5085(17)36134.
    PubMed     Text format    


  2. MONDELLI MU
    Liver MAIT Cells in Hepatitis C: Pathogenetic Role or Innocent Bystanders?
    Gastroenterology. 2017 Oct 4. pii: S0016-5085(17)36186.
    PubMed     Text format    


    September 2017
  3. CHILDS-KEAN LM, Hong J
    Detectable Viremia at the End of Treatment With Direct-Acting Antivirals Can Be Associated With Subsequent Clinical Cure in Patients With Chronic Hepatitis C: A Case Series.
    Gastroenterology. 2017 Sep 4. pii: S0016-5085(17)35912.
    PubMed     Text format    


    August 2017
  4. MAAN R, Feld JJ
    Risk for hepatocellular carcinoma after HCV antiviral therapy with direct-acting antivirals: case closed?
    Gastroenterology. 2017 Aug 31. pii: S0016-5085(17)36085.
    PubMed     Text format    


  5. YU ML
    Resistance-Associated Substitutions in Short Duration of Interferon-Free Direct-Acting Antivirals for Hepatitis C.
    Gastroenterology. 2017 Aug 3. pii: S0016-5085(17)35886.
    PubMed     Text format    


  6. BOLTE FJ, O'Keefe AC, Webb LM, Serti E, et al
    Intra-hepatic Depletion of Mucosal Associated Invariant T cells in Hepatitis C Virus-induced Liver Inflammation.
    Gastroenterology. 2017 Aug 2. pii: S0016-5085(17)35975.
    PubMed     Text format     Abstract available


    July 2017
  7. MISHRA P, Florian J, Peter J, Vainorius M, et al
    Public-Private Partnership: Targeting Real-World Data for Hepatitis C Direct-Acting Antivirals.
    Gastroenterology. 2017 Jul 27. pii: S0016-5085(17)35956.
    PubMed     Text format    


  8. LENS S, Alvarado E, Marino Z, Londono MC, et al
    Effects of All-oral Anti-viral Therapy on HVPG and Systemic Hemodynamics in Patients with Hepatitis C Virus-associated Cirrhosis.
    Gastroenterology. 2017 Jul 19. pii: S0016-5085(17)35922.
    PubMed     Text format     Abstract available


    June 2017
  9. KANWAL F, Kramer J, Asch SM, Chayanupatkul M, et al
    Risk of Hepatocellular Cancer in HCV Patients Treated with Direct Acting Antiviral Agents.
    Gastroenterology. 2017 Jun 19. pii: S0016-5085(17)35797.
    PubMed     Text format     Abstract available


  10. ENOMOTO M, Murakami Y, Kawada N
    Detection of HCV RNA in Sustained Virologic Response to Direct-Acting Antiviral Agents: Occult or Science Fiction?
    Gastroenterology. 2017 Jun 2. pii: S0016-5085(17)35638.
    PubMed     Text format    


  11. DE MARCO L, Pellicano R
    When to Search for Occult Infection After Eradication of Hepatitis C?
    Gastroenterology. 2017 Jun 2. pii: S0016-5085(17)35601.
    PubMed     Text format    


    May 2017
  12. KANWAL F, Bacon BR, Beste LA, Brill JV, et al
    Hepatitis C Virus Infection Care Pathway-A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group.
    Gastroenterology. 2017;152:1588-1598.
    PubMed     Text format    


  13. SINGH S, Muir AJ, Dieterich DT, Falck-Ytter YT, et al
    American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases.
    Gastroenterology. 2017;152:1544-1577.
    PubMed     Text format     Abstract available


    April 2017
  14. LAIDLAW SM, Marukian S, Gilmore RH, Cashman SB, et al
    Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent from Interferons.
    Gastroenterology. 2017 Apr 26. pii: S0016-5085(17)35530.
    PubMed     Text format     Abstract available


  15. JACOBSON IM, Lawitz E, Gane EJ, Willems BE, et al
    Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir In Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
    Gastroenterology. 2017 Apr 5. pii: S0016-5085(17)35399.
    PubMed     Text format     Abstract available


    March 2017
  16. JACOBSON IM, Lim JK, Fried MW
    AGA Institute Clinical Practice Update: Care of Patients Who Have Achieved a Sustained Virologic Response (SVR) Following Antiviral Therapy for Chronic Hepatitis C Infection.
    Gastroenterology. 2017 Mar 23. pii: S0016-5085(17)30327.
    PubMed     Text format     Abstract available


  17. MISHRA P, Chen M
    Direct-Acting Antivirals for Chronic Hepatitis C: Can Drug Properties Signal Potential for Liver Injury?
    Gastroenterology. 2017 Mar 18. pii: S0016-5085(17)30295.
    PubMed     Text format    


  18. SAADOUN D, Pol S, Ferfar Y, Alric L, et al
    Efficacy and Safety of Sofosbuvir plus Daclatasvir for Treatment of HCV-associated Cryoglobulinemia Vasculitis.
    Gastroenterology. 2017 Mar 10. pii: S0016-5085(17)30269.
    PubMed     Text format     Abstract available


  19. COMARMOND C, Garrido M, Pol S, Desbois AC, et al
    Direct-acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-induced Cryoglobulinemia Vasculitis.
    Gastroenterology. 2017 Mar 5. pii: S0016-5085(17)30235.
    PubMed     Text format     Abstract available


    February 2017
  20. AGHEMO A, Colombo M
    Response-Guided Duration of Directly Acting Antiviral Therapy for Chronic Hepatitis C: Back to the Future?
    Gastroenterology. 2017 Feb 27. pii: S0016-5085(17)30205.
    PubMed     Text format    


  21. JACOBSON IM, Lawitz E, Kwo PY, Hezode C, et al
    Safety and Efficacy of Elbasvir/Grazoprevir in Patients with Hepatitis C Virus Infection and Compensated Cirrhosis: an Integrated Analysis.
    Gastroenterology. 2017 Feb 10. pii: S0016-5085(17)30150.
    PubMed     Text format     Abstract available


  22. MATSUURA K, Sawai H, Ikeo K, Ogawa S, et al
    Genome-wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection.
    Gastroenterology. 2017 Feb 2. pii: S0016-5085(17)30130.
    PubMed     Text format     Abstract available


  23. RAVI S, Axley P, Jones D, Kodali S, et al
    Unusually High Rates of Hepatocellular Carcinoma After Treatment With Direct-Acting Antiviral Therapy for Hepatitis C Related Cirrhosis.
    Gastroenterology. 2017 Feb 1. pii: S0016-5085(16)35535.
    PubMed     Text format    


    January 2017
  24. GANE EJ, Hyland RH, Yang Y, Svarovskaia E, et al
    Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection.
    Gastroenterology. 2017 Jan 27. pii: S0016-5085(17)30074.
    PubMed     Text format     Abstract available


  25. GOLDBERG D, Ditah IC, Saeian K, Lalehzari M, et al
    Changes in the Prevalence of Hepatitis C Virus Infection, Non-alcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients with Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.
    Gastroenterology. 2017 Jan 11. pii: S0016-5085(17)30014.
    PubMed     Text format     Abstract available


    December 2016
  26. KOUTSOUDAKIS G, Perez-Del-Pulgar S, Forns X
    Occult Hepatitis C Virus Infection: Are We Digging Too Deep?
    Gastroenterology. 2016 Dec 27. pii: S0016-5085(16)35528.
    PubMed     Text format    


  27. BOSON B, Denolly S, Turlure F, Chamot C, et al
    Daclatasvir Prevents Hepatitis C Virus by Blocking Transfer of Viral Genome to Assembly Sites.
    Gastroenterology. 2016 Dec 5. pii: S0016-5085(16)35447.
    PubMed     Text format     Abstract available


    November 2016
  28. COLPITTS CC, Baumert TF
    SMAD about HCV cell entry and pathogenesis of liver disease.
    Gastroenterology. 2016 Nov 23. pii: S0016-5085(16)35398.
    PubMed     Text format    


  29. DONNELLY MC, Imlach SN, Abravanel F, Ramalingam S, et al
    Sofosbuvir and Daclatasvir Anti-Viral Therapy Fails to Clear HEV Viremia and Restore Reactive T Cells in a HEV/HCV Co-Infected Liver Transplant Recipient.
    Gastroenterology. 2016 Nov 21. pii: S0016-5085(16)34895.
    PubMed     Text format    


  30. ELMASRY S, Wadhwa S, Bang BR, Cook L, et al
    Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-acting Antiviral Agents for Recurrent Infection After Liver Transplantation.
    Gastroenterology. 2016 Nov 9. pii: S0016-5085(16)35323.
    PubMed     Text format     Abstract available


  31. WANG W, Hakim MS, Nair VP, de Ruiter PE, et al
    Distinct Antiviral Potency of Sofosbuvir against Hepatitis C and E Viruses.
    Gastroenterology. 2016 Nov 1. pii: S0016-5085(16)35194.
    PubMed     Text format    


    October 2016
  32. KOMATSU TE, Boyd S, Sherwat A, Tracy L, et al
    Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.
    Gastroenterology. 2016 Oct 20. pii: S0016-5085(16)35241.
    PubMed     Text format     Abstract available


  33. LIANG TJ
    Hepatitis C Virus: from Obscurity to the Lasker.
    Gastroenterology. 2016 Oct 17. pii: S0016-5085(16)35233.
    PubMed     Text format    


  34. KWO P, Gane E, Peng CY, Pearlman B, et al
    Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients with Chronic Hepatitis C Infection.
    Gastroenterology. 2016 Oct 5. pii: S0016-5085(16)35170.
    PubMed     Text format     Abstract available


  35. AGHEMO A, Buti M
    Hepatitis C Therapy: Game Over!
    Gastroenterology. 2016 Oct 1. pii: S0016-5085(16)35131.
    PubMed     Text format    


    September 2016
  36. ZHANG F, Sodroski C, Cha H, Li Q, et al
    Infection of Hepatocytes with HCV Increases Cell Surface Levels of Heparan Sulfate Proteoglycans, Uptake of Cholesterol and Lipoprotein, and Virus Entry by Upregulating SMAD6 and SMAD7.
    Gastroenterology. 2016 Sep 29. pii: S0016-5085(16)35128.
    PubMed     Text format     Abstract available


  37. NAHON P, Bourcier V, Layese R, Audureau E, et al
    Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.
    Gastroenterology. 2016 Sep 15. pii: S0016-5085(16)35070.
    PubMed     Text format     Abstract available


    August 2016
  38. PAWLOTSKY JM
    Hepatitis C Drugs: Is Next Generation the Last Generation?
    Gastroenterology. 2016 Aug 30. pii: S0016-5085(16)34985.
    PubMed     Text format    


  39. TERRAULT NA, Zeuzem S, Di Bisceglie AM, Lim JK, et al
    Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated of Sustained Virologic Response.
    Gastroenterology. 2016 Aug 23. pii: S0016-5085(16)34927.
    PubMed     Text format     Abstract available


    July 2016
  40. LAWITZ E, Reau N, Hinestrosa F, Rabinovitz M, et al
    Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients with Genotype 1 Hepatitis C Virus Infection in an Open-label, Phase 2 Trial.
    Gastroenterology. 2016 Jul 30. pii: S0016-5085(16)34835.
    PubMed     Text format     Abstract available


  41. GANE E, Kowdley KV, Pound D, Stedman CA, et al
    Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients with HCV Genotype 2, 3, 4, or 6 Infections in an Open-label, Phase 2 Trial.
    Gastroenterology. 2016 Jul 30. pii: S0016-5085(16)34834.
    PubMed     Text format     Abstract available


  42. AFDHAL NH, Serfaty L
    Cohort Studies and Registries in the treatment of HCV; the impact of "real life" effectiveness.
    Gastroenterology. 2016 Jul 22. pii: S0016-5085(16)34820.
    PubMed     Text format    


  43. GANE E, Poordad F, Wang S, Asatryan A, et al
    High Efficacy of ABT-493 and ABT-530 in Patients with HCV Genotype 1 or 3 Infection and Compensated Cirrhosis.
    Gastroenterology. 2016 Jul 22. pii: S0016-5085(16)34816.
    PubMed     Text format     Abstract available


  44. RAMIREZ S, Mikkelsen LS, Gottwein JM, Bukh J, et al
    Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir.
    Gastroenterology. 2016 Jul 21. pii: S0016-5085(16)34809.
    PubMed     Text format     Abstract available


  45. SHIN JY, Azoulay L, Filion KB
    Statin Use in Patients With Hepatitis C-related Cirrhosis: True Benefit or Immortal Time Bias?
    Gastroenterology. 2016 Jul 1. pii: S0016-5085(16)34434.
    PubMed     Text format    


    June 2016
  46. GAMBATO M, Perez-Del-Pulgar S, Hedskog C, Svarovskia ES, et al
    HCV RNA Persists in Liver Explants of Most Patients Awaiting Liver Transplantation Treated With an Interferon-Free Regimen.
    Gastroenterology. 2016 Jun 30. pii: S0016-5085(16)34697.
    PubMed     Text format     Abstract available


  47. SARRAZIN C, Dvory-Sobol H, Svarovskaia ES, Doehle B, et al
    Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment with Ledipasvir and Sofosbuvir.
    Gastroenterology. 2016 Jun 10. pii: S0016-5085(16)34614.
    PubMed     Text format     Abstract available


  48. IOANNOU GN, Beste LA, Chang MF, Green PK, et al
    Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Healthcare System.
    Gastroenterology. 2016 Jun 4. pii: S0016-5085(16)34575.
    PubMed     Text format     Abstract available


    May 2016
  49. GANE EJ, Schwabe C, Hyland RH, Yang Y, et al
    Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-naive or Previously Treated Patients with HCV Genotype 1 or 3 Infections.
    Gastroenterology. 2016 May 27. pii: S0016-5085(16)34513.
    PubMed     Text format     Abstract available


  50. KLINGE MJ, Borhani AA, Malik SM
    Hepatitis C and Numerous Disappearing Hepatic Nodules: No-dule C It, No-dule Don't.
    Gastroenterology. 2016 May 27. pii: S0016-5085(16)30099.
    PubMed     Text format    


    April 2016
  51. PAWLOTSKY JM
    Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens.
    Gastroenterology. 2016 Apr 11. pii: S0016-5085(16)30055.
    PubMed     Text format     Abstract available


    March 2016
  52. DI MARCO V, Calvaruso V, Ferraro D, Bavetta MG, et al
    Effects of Viral Eradication in Patients with HCV and Cirrhosis Differ With Stage of Portal Hypertension.
    Gastroenterology. 2016 Mar 31. pii: S0016-5085(16)30049.
    PubMed     Text format     Abstract available


  53. AGHEMO A, Colombo M
    No Time for Bullies in Hepatitis C Virus Therapy: Genotype 3 Conquered?
    Gastroenterology. 2016 Mar 24. pii: S0016-5085(16)00378.
    PubMed     Text format    


  54. POCKROS PJ, Reddy KR, Mantry PS, Cohen E, et al
    Efficacy of Direct-acting Antiviral Combination for Patients with HCV Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.
    Gastroenterology. 2016 Mar 11. pii: S0016-5085(16)00326.
    PubMed     Text format     Abstract available


    February 2016
  55. YOUNOSSI Z, Park H, Henry L, Adeyemi A, et al
    Extra-Hepatic Manifestations of Hepatitis C-a Meta-Analysis of Prevalence, Quality of Life, and Economic Burden.
    Gastroenterology. 2016 Feb 25. pii: S0016-5085(16)00230.
    PubMed     Text format     Abstract available


  56. HASSAN T, Khan F, Kyprianou A
    A Not So Benign Abdomen!
    Gastroenterology. 2016;150:e1-2.
    PubMed     Text format    


    January 2016
  57. XIA Y, Stadler D, Lucifora J, Reisinger F, et al
    Interferon-gamma and Tumor Necrosis Factor-alpha Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis.
    Gastroenterology. 2016;150:194-205.
    PubMed     Text format     Abstract available


    November 2015
  58. RAZIORROUH B, Sacher K, Tawar RG, Emmerich F, et al
    Virus-specific CD4+ T Cells Have Functional and Phenotypic Characteristics of Follicular T-helper Cells in Patients With Acute and Chronic HCV Infections.
    Gastroenterology. 2015 Nov 13. pii: S0016-5085(15)01622.
    PubMed     Text format     Abstract available


    October 2015
  59. WHITE DL, Richardson P, Tayoub N, Davila JA, et al
    The Updated Model: An Adjusted Serum Alpha-Fetoprotein-Based Algorithm for Hepatocellular Carcinoma Detection With Hepatitis C Virus-Related Cirrhosis.
    Gastroenterology. 2015 Oct 28. pii: S0016-5085(15)01435.
    PubMed     Text format    


  60. SULKOWSKI MS, Vargas HE, Di Bisceglie AM, Kuo PA, et al
    Effectiveness of Simeprevir plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients with HCV Genotype 1 Infection.
    Gastroenterology. 2015 Oct 21. pii: S0016-5085(15)01507.
    PubMed     Text format     Abstract available


  61. MOHANTY A, Tate J, Garcia-Tsao G
    Statins are Associated with a Decreased Risk of Decompensation and Death in Veterans with Hepatitis C-related Compensated Cirrhosis.
    Gastroenterology. 2015 Oct 17. pii: S0016-5085(15)01476.
    PubMed     Text format     Abstract available


    September 2015
  62. BACK DJ, Burger DM
    Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: Potential mechanisms and lessons to be learned.
    Gastroenterology. 2015 Sep 25. pii: S0016-5085(15)01387.
    PubMed     Text format    


  63. FAUVELLE C, Felmlee DJ, Crouchet E, Lee J, et al
    Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies.
    Gastroenterology. 2015 Sep 21. pii: S0016-5085(15)01358.
    PubMed     Text format     Abstract available


  64. PETTA S, Maida M, Macaluso FS, Barbara M, et al
    Hepatitis C Virus Infection is Associated With Increased Cardiovascular Mortality: A Meta-analysis of Observational Studies.
    Gastroenterology. 2015 Sep 16. pii: S0016-5085(15)01322.
    PubMed     Text format     Abstract available


    August 2015
  65. NEGRO F, Forton D, Craxi A, Sulkowski MS, et al
    Extra-hepatic Morbidity and Mortality of Chronic Hepatitis C.
    Gastroenterology. 2015 Aug 25. pii: S0016-5085(15)01203.
    PubMed     Text format     Abstract available


  66. GANE EJ, Hyland RH, An D, Svarovskaia E, et al
    Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection.
    Gastroenterology. 2015 Aug 7. pii: S0016-5085(15)01096.
    PubMed     Text format     Abstract available


  67. BESTE LA, Leipertz SL, Green PK, Dominitz JA, et al
    Trends in the burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US Veterans from 2001-2013.
    Gastroenterology. 2015 Aug 5. pii: S0016-5085(15)01088.
    PubMed     Text format     Abstract available


  68. FOSTER GR, Pianko S, Brown A, Forton D, et al
    Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-alfa in Patients With HCV Genotype 3 Infection and Treatment-Experienced Patients with Cirrhosis and HCV Genotype 2 Infection.
    Gastroenterology. 2015 Aug 3. pii: S0016-5085(15)01069.
    PubMed     Text format     Abstract available


  69. HSU YC, Wu CY
    Reply.
    Gastroenterology. 2015;149:501-2.
    PubMed     Text format    


    July 2015
  70. LAWITZ E, Makara M, Akarca US, Thuluvath PJ, et al
    Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-label Study of Patients With Genotype 1b Chronic Hepatitis C Virus, With and Without Cirrhosis.
    Gastroenterology. 2015 Jul 10. pii: S0016-5085(15)00936.
    PubMed     Text format     Abstract available


    June 2015
  71. AGHEMO A, Colombo M
    Will the Benefits of Treatment for Chronic Hepatitis C Be Retained in the Interferon-free Era?
    Gastroenterology. 2015 Jun 27. pii: S0016-5085(15)00894.
    PubMed     Text format    


    May 2015
  72. MONDELLI MU
    Direct-Acting Antivirals Cure Innate Immunity in Chronic Hepatitis C.
    Gastroenterology. 2015 May 26. pii: S0016-5085(15)00720.
    PubMed     Text format    


  73. CHARLTON M, Everson GT, Flamm SL, Kumar P, et al
    Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease.
    Gastroenterology. 2015 May 15. pii: S0016-5085(15)00682.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: